

30th Annual Scientific Session and Exhibition of the American Society of Nuclear Cardiology

Accurate Quantitation of Cardiac Amyloidosis by ¹²⁴I-Evuzamitide Compared to Extracellular Volume

Alyssa de Moraes, Annu Kurian, Tony Chen, Ardel J. Romero Pabon, Olivier F. Clerc, Sarah Cuddy, and Sharmila Dorbala Brigham and Women's Hospital, Boston, MA, USA

Disclosures: A. de Moraes: None. A. Kurian: None. T. Chen: None. A.J. Romero Pabon: None. O.F. Clerc: Research grant from the International Society of Amyloidosis, American Society of Nuclear Cardiology, Pfizer. Cuddy: Site for Helios-B (Alnylam), for Cardio-TTRansform (Ionis, AstraZeneca), for DepleTTR (Alexion), personal fees from Pfizer, BridgeBio, Ionis, AstraZeneca, Alexion, Life Molecular Imaging, Attralus, Novo Nordisk. S. Dorbala: Research grant from Pfizer, General Electric Healthcare, Attralus, Siemens, Philips, consulting fees from Pfizer.

Case Presentation

62-year-old man: Exertional dyspnea and chest pain, hepatomegaly

Laboratory values:

Hemoglobin6.8 g/L

Alkaline phosphatase 887 U/L, then 1347 U/L

• γ-GT 820 U/L

Bilirubin
Normal, then up to 8.3 mg/dL (mostly direct)

NT-proBNP
Normal, then 2569 pg/mL

24h urine protein2.2 g

• Serum electrophoresis M-spike $IgG \lambda + high \lambda$ free light chains

Bone marrow biopsy: Multiple myeloma IgG λ with 80% plasmacytes


Skin biopsy with MS: Light chain λ amyloidosis (AL)


Echocardiography: OK except grade 2 DD, speckled myocardium (?)


Cardiac MRI: No LGE, high T1, extracellular volume (ECV) 48%

¹²⁴I-Evuzamitide PET/CT









Teaching Points

- ➤ ¹²⁴I-evuzamitide PET/CT can detect and quantify organ involvement in AL amyloidosis (e.g., heart, liver, spleen).
- ➤ ECV from MRI can be inaccurate with anemia, and includes non-amyloid components of the extracellular matrix.
- ➤ ¹²⁴I-evuzamitide has the unique ability to detect liver amyloid, which may avoid biopsy, unlike other amyloid PET radiotracers.